U.S., Aug. 28 -- ClinicalTrials.gov registry received information related to the study (NCT07790575) titled 'Autoimmune Cytopenia Elimination by Chimeric Antigen Receptor T-cell Therapy' on Aug. 24.
Brief Summary: This is a phase 1 study to evaluate the safety and tolerability of AZD0120 in patients with relapsed or refractory immune mediated cytopenia (primary chronic Immune Thrombocytopenia (ITP) or autoimmune hemolytic anemia (wAIHA)).
Study Start Date: Sept., 2026
Study Type: INTERVENTIONAL
Condition:
Cytopenia
Intervention:
DRUG: AZD0120
One time administration on Day 0.
DRUG: Bendamustin
Participants will be given bendamustin for 2 days (study Day -5 and Day -4) followed by 3 days of rest.
Recruitment Status: NOT_YET_RECRUI...